<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ldt</journal-id><journal-title-group><journal-title xml:lang="ru">Лучевая диагностика и терапия</journal-title><trans-title-group xml:lang="en"><trans-title>Diagnostic radiology and radiotherapy</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-5343</issn><publisher><publisher-name>Baltic Medical Education Center</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.22328/2079-5343-2026-17-2-51-60</article-id><article-id custom-type="elpub" pub-id-type="custom">ldt-1248</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Нативное Т1-картирование и фракция внеклеточного объема печени и селезенки в стратификации цирроза печени по классам шкалы Чайлд-Пью: ретроспективное исследование</article-title><trans-title-group xml:lang="en"><trans-title>NATIVE T1 mapping and liver and splenic extracellular volume fraction in the stratification of liver cirrhosis according to Child-Pugh classes: a retrospective study</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8258-522X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Савченков</surname><given-names>Ю. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Savchenkov</surname><given-names>Yu. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Савченков Юрий Николаевич - кандидат медицинских наук, ассистент кафедры лучевой диагностики с курсом радиологии Медико-биологического университета инноваций и непрерывного образования ; заведующий отделением лучевой диагностики</p><p>123098, Москва, ул. Маршала Новикова, д. 23;  109263, Москва, ул. Шкулева, д. 4</p></bio><bio xml:lang="en"><p>Yury N. Savchenkov - Cand. of Sci. (Med.), assistant of the Dept of Radiation Diagnostics with a course in Radiology Diagnostics at the Medical and Biological University of Innovation and Continuing Education ; Head of the Dept of Radiation Diagnostics </p><p>109263, Moscow, Shkuleva str., 4</p></bio><email xlink:type="simple">yura_savchenkov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1611-5000</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Труфанов</surname><given-names>Г. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Trufanov</surname><given-names>G. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Труфанов Геннадий Евгеньевич - доктор медицинских наук, профессор, главный научный сотрудник НИО лучевой диагностики, заведующий кафедрой лучевой диагностики и медицинской визуализации с клиникой</p><p>197341, Санкт-Петербург, ул. Аккуратова, д. 2</p></bio><bio xml:lang="en"><p>Gennadiy E. Trufanov - Dr. of Sci. (Med.), Professor, Chief Researcher of the Research Institute of Radiation Diagnostics, Head of the Dept of Radiation Diagnostics and Medical Imaging with the clinic</p><p>197341, St. Petersburg, Akkuratova str., 2</p></bio><email xlink:type="simple">trufanovge@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2937-6322</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фокин</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Fokin</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Фокин Владимир Александрович - доктор медицинских наук, профессор кафедры лучевой диагностики и медицинской визуализации с клиникой Института медицинского образования</p><p>197341, Санкт-Петербург, ул. Аккуратова, д. 2</p></bio><bio xml:lang="en"><p>Vladimir A. Fokin - Dr. of Sci. (Med.), Professor of the Dept of Radiation Diagnostics and Medical Imaging with the clinic</p><p>197341, St. Petersburg, Akkuratova str., 2</p></bio><email xlink:type="simple">vladfokin@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6084-2061</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ионова</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Ionova</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ионова Елена Александровна - доктор медицинских наук, заведующий кафедрой лучевой диагностики с курсом радиологии Медико-биологического университета инноваций и непрерывного образования ф</p><p>123098, Москва, ул. Маршала Новикова, д. 23</p></bio><bio xml:lang="en"><p>Elena A. Ionova - Dr. of Sci. (Med.), Professor, Head of the Dept of Radiation Diagnostics with a course in Radiology Diagnostics at the Medical and Biological University of Innovation and Continuing Education</p><p>123098, Moscow, Marshala Novikova str., 23</p></bio><email xlink:type="simple">ionela60@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-0100-0306</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Савченкова</surname><given-names>А. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Savchenkova</surname><given-names>A. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Савченкова Алина Петровна - врач-рентгенолог</p><p>127051, Москва, ул. Петровка, д. 24, стр. 1</p></bio><bio xml:lang="en"><p>Alina P. Savchenkova - radiologist </p><p>127051, Moscow, Petrovka str., 24, building 1</p></bio><email xlink:type="simple">alinchik25@mail.ru</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-6719-4900</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Просиков</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Prosikov</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Просиков Валентин Андреевич - врач-рентгенолог отделения лучевой диагностики</p><p>109263, Москва, ул. Шкулева, д. 4</p></bio><bio xml:lang="en"><p>Valentin A. Prosikov - radiologist at the Dept of Radiation Diagnostics </p><p>109263, Moscow, Shkuleva str., 4</p></bio><email xlink:type="simple">prosikov92@mail.ru</email><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3911-8543</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Аракелов</surname><given-names>С. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Arakelov</surname><given-names>S. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Аракелов Сергей Эрнестович - доктор медицинских наук, профессор, заведующий кафедрой семейной медицины с курсом паллиативной медицинской помощи;  главный врач </p><p>109263, Москва, ул. Шкулева, д. 4</p></bio><bio xml:lang="en"><p>Sergey E. Arakelov - Dr. of Sci. (Med.), Professor, Head of the Department of Family Medicine with a Palliative Care Course ; Chief Physician </p><p>109263, Moscow, Shkuleva str., 4</p></bio><email xlink:type="simple">arakelov-s@yandex.ru</email><xref ref-type="aff" rid="aff-6"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Городская клиническая больница имени В. П. Демихова; Федеральный медицинский биофизический центр имени А. И. Бурназяна</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V. P. Demikhov City Clinical Hospital, Moscow Healthcare Department; A. I. Burnazyan Federal Medical Biophysical Center, Federal Medical Biological Agency of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр имени В. А. Алмазова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V. A. Almazov National Medical Research Centre</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Федеральный медицинский биофизический центр имени А. И. Бурназяна</institution><country>Россия</country></aff><aff xml:lang="en"><institution>A. I. Burnazyan Federal Medical Biophysical Center, Federal Medical Biological Agency of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Научно-практический клинический центр диагностики и телемедицинских технологий</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Scientific and Practical Clinical Center for Diagnostics and Telemedicine Technologies, Moscow Healthcare Department</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>Городская клиническая больница имени В. П. Демихова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V. P. Demikhov City Clinical Hospital, Moscow Healthcare Department</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-6"><aff xml:lang="ru"><institution>Городская клиническая больница имени В. П. Демихова; Российский университет дружбы народов имени Патриса Лумумбы</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V. P. Demikhov City Clinical Hospital, Moscow Healthcare Department; Patrice Lumumba Peoples’ Friendship University of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>24</day><month>07</month><year>2026</year></pub-date><volume>17</volume><issue>2</issue><fpage>51</fpage><lpage>60</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Савченков Ю.Н., Труфанов Г.Е., Фокин В.А., Ионова Е.А., Савченкова А.П., Просиков В.А., Аракелов С.Э., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Савченков Ю.Н., Труфанов Г.Е., Фокин В.А., Ионова Е.А., Савченкова А.П., Просиков В.А., Аракелов С.Э.</copyright-holder><copyright-holder xml:lang="en">Savchenkov Y.N., Trufanov G.E., Fokin V.A., Ionova E.A., Savchenkova A.P., Prosikov V.A., Arakelov S.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://radiag.bmoc-spb.ru/jour/article/view/1248">https://radiag.bmoc-spb.ru/jour/article/view/1248</self-uri><abstract><sec><title>ВВЕДЕНИЕ</title><p>ВВЕДЕНИЕ: Цирроз печени является конечной стадией хронических заболеваний печени и сопровождается развитием портальной гипертензии, что приводит к изменению количественных магнитно-резонансных (МР)-показателей печени и селезенки. Неинвазивные методики, включая нативное Т1-картирование и расчет фракции внеклеточного объема (ФВО), рассматриваются как перспективные инструменты стратификации тяжести заболевания, однако их сравнительная диагностическая эффективность при распределении пациентов по классам шкалы оценки тяжести и компенсации цирроза Чайлд-Пью изучена недостаточно.</p></sec><sec><title>ЦЕЛЬ</title><p>ЦЕЛЬ: Оценить и сравнить диагностическую эффективность нативного Т1-картирования и ФВО печени и селезенки при стратификации цирроза печени по классам шкалы оценки тяжести и компенсации цирроза Чайлд-Пью. </p></sec><sec><title>МАТЕРИАЛЫ И МЕТОДЫ</title><p>МАТЕРИАЛЫ И МЕТОДЫ: Ретроспективное исследование включало обследование 50 пациентов с подтвержденным циррозом печени, которым выполнена мультипараметрическая магнитно-резонансная томография (МРТ) с нативным Т1-картированием (протоколы MOLLI 4(1)3(1)2 и 5(3)3) и расчетом ФВО печени и селезенки. Пациентов стратифицировали по классам Чайлд-Пью: A (n=31), B (n=13), C (n=6).</p></sec><sec><title>Статистика</title><p>Статистика: Проведен межгрупповой анализ (критерии Крускала–Уоллиса, Манна–Уитни с поправкой Бенджамини-Хохберга, FDR), корреляционный анализ Спирмена и ROC-анализ с расчетом площади под кривой (AUROC) и попарным сравнением кривых (тест Делонга).</p></sec><sec><title>РЕЗУЛЬТАТЫ</title><p>РЕЗУЛЬТАТЫ: Выявлены статистически значимые межгрупповые различия для всех количественных МР-показателей (p≤0,002; FDR &lt;0,05). ФВО печени продемонстрировала наивысшую дискриминационную способность (AUROC 1,000 — A vs C; 0,985 и 0,954 — A vs B; 0,986 — B vs C). Нативное Т1-картирование печени характеризовалось умеренной эффективностью (AUROC 0,728–0,893). Нативное Т1-картирование селезенки показало более низкие и вариабельные значения AUROC (0,436–0,857). ФВО селезенки уступала ФВО печени по диагностической эффективности (AUROC 0,812–0,971). Наиболее сильная корреляция с суммарным баллом по шкале Чайлд-Пью отмечена для ФВО печени (r 0,879–0,892; p&lt;0,001).</p></sec><sec><title>ОБСУЖДЕНИЕ</title><p>ОБСУЖДЕНИЕ: Полученные данные отражают более высокую специфичность ФВО печени по сравнению с интегральными показателями нативного Т1-картирования в отношении функциональной тяжести цирроза печени по шкале Чайлд-Пью. ФВО селезенки преимущественно характеризует гемодинамические проявления портальной гипертензии и менее тесно связана с нарастанием печеночно-клеточной недостаточности.</p></sec><sec><title>ЗАКЛЮЧЕНИЕ</title><p>ЗАКЛЮЧЕНИЕ: ФВО печени является наиболее точным и информативным количественным МР-показателем при стратификации цирроза по классам шкалы Чайлд-Пью, превосходя по диагностической ценности Т1-картирование печени, ФВО селезенки и Т1-картирование селезенки.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>INTRODUCTION</title><p>INTRODUCTION: Liver cirrhosis represents the end stage of chronic liver diseases and is associated with the development of portal hypertension, leading to alterations in quantitative magnetic resonance (MR) parameters of the liver and spleen. Noninvasive techniques, including native T1 mapping and extracellular volume fraction (ECV) calculation, are considered promising tools for disease severity stratification; however, their comparative diagnostic performance in classifying patients according to the Child-Pugh grading system remains insufficiently investigated.</p></sec><sec><title>OBJECTIVE</title><p>OBJECTIVE: To evaluate and compare the diagnostic performance of native T1 mapping and liver and splenic extracellular volume fraction for stratifying liver cirrhosis according to Child-Pugh classes.</p></sec><sec><title>MATERIALS AND METHODS</title><p>MATERIALS AND METHODS: This retrospective study included 50 patients with confirmed liver cirrhosis who underwent multiparametric magnetic resonance imaging (MRI) with native T1 mapping (MOLLI 4(1)3(1)2 and 5(3)3 protocols) and calculation of liver and spleen extracellular volume fraction (ECV). Patients were stratified according to Child-Pugh classes: A (n=31), B (n=13), and C (n=6).</p></sec><sec><title>Statistics</title><p>Statistics: Intergroup analysis was performed using the Kruskal-Wallis and Mann-Whitney tests with Benjamini-Hochberg correction (FDR), along with Spearman correlation analysis and ROC analysis with calculation of the area under the curve (AUROC) and pairwise comparison of ROC curves using the DeLong test.</p></sec><sec><title>RESULTS</title><p>RESULTS: Statistically significant intergroup differences were observed for all quantitative MRI parameters (p≤0.002; FDR &lt;0.05). Liver extracellular volume fraction (ECV) demonstrated the highest discriminative performance (AUROC 1.000 for A vs C; 0.985 and 0.954 for A vs B; 0.986 for B vs C). Native liver T1 mapping showed moderate diagnostic efficiency (AUROC 0.728–0.893). Native spleen T1 mapping yielded lower and more variable AUROC values (0.436–0.857). Spleen ECV was inferior to liver ECV in diagnostic performance (AUROC 0.812–0.971). The strongest correlation with the total Child-Pugh score was observed for liver ECV (r 0.879–0.892; p&lt;0.001).</p></sec><sec><title>DISCUSSION</title><p>DISCUSSION: The findings indicate higher specificity of liver ECV compared with integral native T1 mapping parameters in reflecting the functional severity of cirrhosis according to the Child-Pugh classification. Spleen ECV primarily reflects hemodynamic manifestations of portal hypertension and is less closely associated with progression of hepatocellular insufficiency. </p></sec><sec><title>CONCLUSION</title><p>CONCLUSION: Liver ECV is the most accurate and informative quantitative MR parameter for stratifying cirrhosis according to Child-Pugh classes, outperforming native liver T1 mapping, spleen ECV, and spleen T1 mapping in diagnostic value.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>цирроз печени</kwd><kwd>шкала Чайлд-Пью</kwd><kwd>фракция внеклеточного объема</kwd><kwd>Т1-картирование</kwd><kwd>магнитнорезонансная томография</kwd><kwd>портальная гипертензия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>liver cirrhosis</kwd><kwd>Child-Pugh score</kwd><kwd>extracellular volume fraction</kwd><kwd>T1 mapping</kwd><kwd>magnetic resonance imaging</kwd><kwd>portal hypertension</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Tham E.K.J., Tan D.J.H., Danpanichkul P. et al. The Global Burden of Cirrhosis and Other Chronic Liver Diseases in 2021 // Liver Int. 2025 Vol. 45. P. e70001. doi: 10.1111/liv.70001.</mixed-citation><mixed-citation xml:lang="en">Tham E.K.J., Tan D.J.H., Danpanichkul P. et al. The Global Burden of Cirrhosis and Other Chronic Liver Diseases in 2021 // Liver Int. 2025 Vol. 45. P. e70001. doi: 10.1111/liv.70001.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Cerrito L., Galasso L., Iaccarino J. et al. Present and Future Perspectives in the Treatment of Liver Fibrosis // Pharmaceuticals. 2025. Vol. 18, No. 9. P. 1321. doi: 10.3390/ph18091321.</mixed-citation><mixed-citation xml:lang="en">Cerrito L., Galasso L., Iaccarino J. et al. Present and Future Perspectives in the Treatment of Liver Fibrosis // Pharmaceuticals. 2025. Vol. 18, No. 9. P. 1321. doi: 10.3390/ph18091321.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Zeng X., Huang D., Zhu Z. et al. Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective // Front. Pharmacol. 2025 Vol. 16. P. 1574385. doi: 10.3389/fphar.2025.1574385.</mixed-citation><mixed-citation xml:lang="en">Zeng X., Huang D., Zhu Z. et al. Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective // Front. Pharmacol. 2025 Vol. 16. P. 1574385. doi: 10.3389/fphar.2025.1574385.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Tarannum S., Ilyas T., Tarannum Shaik S. et al. Assessment of the Child-Pugh Score, Model for End-Stage Liver Disease Score, Fibrosis-4 Index, and AST to Platelet Ratio Index as Non-endoscopic Predictors of the Presence of Esophageal Varices and Variceal Bleeding in Chronic Liver Disease Patients // Cureus. 2024. Vol. 16, No. 11. P. e73768. doi: 10.7759/cureus.73768.</mixed-citation><mixed-citation xml:lang="en">Tarannum S., Ilyas T., Tarannum Shaik S. et al. Assessment of the Child-Pugh Score, Model for End-Stage Liver Disease Score, Fibrosis-4 Index, and AST to Platelet Ratio Index as Non-endoscopic Predictors of the Presence of Esophageal Varices and Variceal Bleeding in Chronic Liver Disease Patients // Cureus. 2024. Vol. 16, No. 11. P. e73768. doi: 10.7759/cureus.73768.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Costa F., Wiedenmann B., Roderburg C., Mohr R., Abou-Alfa G.K. Systemic treatment in patients with Child-Pugh B liver dysfunction and advanced hepatocellular carcinoma // Cancer Med. 2023. Vol.12, No. 12. P. 12766–12778. doi: 10.1002/cam4.6033.</mixed-citation><mixed-citation xml:lang="en">Costa F., Wiedenmann B., Roderburg C., Mohr R., Abou-Alfa G.K. Systemic treatment in patients with Child-Pugh B liver dysfunction and advanced hepatocellular carcinoma // Cancer Med. 2023. Vol.12, No. 12. P. 12766–12778. doi: 10.1002/cam4.6033.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Huang W., Peng Y., Kang L. Advancements of non-invasive imaging technologies for the diagnosis and staging of liver fibrosis: Present and future // VIEW. 2024. doi: 10.1002/VIW.20240010.</mixed-citation><mixed-citation xml:lang="en">Huang W., Peng Y., Kang L. Advancements of non-invasive imaging technologies for the diagnosis and staging of liver fibrosis: Present and future // VIEW. 2024. doi: 10.1002/VIW.20240010.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Xue S., Zhu Y., Shao M. et al. T1/T2 mapping as a non-invasive method for evaluating liver fibrosis based on correlation of biomarkers: a preclinical study // BMC Gastroenterol. 2025. Vol. 25, No. 1. P. 122. doi: 10.1186/s12876-025-03701-9.</mixed-citation><mixed-citation xml:lang="en">Xue S., Zhu Y., Shao M. et al. T1/T2 mapping as a non-invasive method for evaluating liver fibrosis based on correlation of biomarkers: a preclinical study // BMC Gastroenterol. 2025. Vol. 25, No. 1. P. 122. doi: 10.1186/s12876-025-03701-9.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Serai S.D., Robson M.D., Tirkes T., Trout A.T. T1 Mapping of the Abdomen, From the AJR «How We Do It” Special Series // AJR Am. J. Roentgenol. 2025. Vol. 224. P. 6. doi: 10.2214/AJR.24.31643.</mixed-citation><mixed-citation xml:lang="en">Serai S.D., Robson M.D., Tirkes T., Trout A.T. T1 Mapping of the Abdomen, From the AJR «How We Do It” Special Series // AJR Am. J. Roentgenol. 2025. Vol. 224. P. 6. doi: 10.2214/AJR.24.31643.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Mesropyan N., Chang J., Lutz P. et al. Clinical validation of T1r mapping for the assessment of hepatic fibrosis in patients with chronic liver disease // Eur. Radiol. 2025. doi: 10.1007/s00330-025-12225-5.</mixed-citation><mixed-citation xml:lang="en">Mesropyan N., Chang J., Lutz P. et al. Clinical validation of T1r mapping for the assessment of hepatic fibrosis in patients with chronic liver disease // Eur. Radiol. 2025. doi: 10.1007/s00330-025-12225-5.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Obmann V.C., Ardoino M., Klaus J. et al. MRI Extracellular Volume Fraction in Liver Fibrosis-A Comparison of Different Time Points and Blood Pool Measurements // J. Magn. Reson. Imaging. 2024. Vol. 60, No. 4. P. 1678–1688. doi: 10.1002/jmri.29259.</mixed-citation><mixed-citation xml:lang="en">Obmann V.C., Ardoino M., Klaus J. et al. MRI Extracellular Volume Fraction in Liver Fibrosis-A Comparison of Different Time Points and Blood Pool Measurements // J. Magn. Reson. Imaging. 2024. Vol. 60, No. 4. P. 1678–1688. doi: 10.1002/jmri.29259.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Mesropyan N., Kupczyk P., Dold L. et al. Non-invasive assessment of liver fibrosis in autoimmune hepatitis: Diagnostic value of liver magnetic resonance parametric mapping including extracellular volume fraction // Abdom. Radiol (NY). 2021. Vol. 46, No. 6. P. 2458–2466. doi: 10.1007/s00261-020-02822-x.</mixed-citation><mixed-citation xml:lang="en">Mesropyan N., Kupczyk P., Dold L. et al. Non-invasive assessment of liver fibrosis in autoimmune hepatitis: Diagnostic value of liver magnetic resonance parametric mapping including extracellular volume fraction // Abdom. Radiol (NY). 2021. Vol. 46, No. 6. P. 2458–2466. doi: 10.1007/s00261-020-02822-x.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Mesropyan N., Isaak A., Faron A. et al. Magnetic resonance parametric mapping of the spleen for non-invasive assessment of portal hypertension // Eur. Radiol. 2021. Vol. 31, No. 1. P. 85–93. doi: 10.1007/s00330-020-07080-5.</mixed-citation><mixed-citation xml:lang="en">Mesropyan N., Isaak A., Faron A. et al. Magnetic resonance parametric mapping of the spleen for non-invasive assessment of portal hypertension // Eur. Radiol. 2021. Vol. 31, No. 1. P. 85–93. doi: 10.1007/s00330-020-07080-5.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Khan F., Dsouza S., Khamis A.H. et al. Noninvasive Assessment of the Severity of Liver Fibrosis in MASLD Patients with Long-Standing Type 2 Diabetes // J. Gen. Intern. Med. 2025. Vol. 40, No. 10. P. 2309–2318. doi: 10.1007/s11606-025-09348-2.</mixed-citation><mixed-citation xml:lang="en">Khan F., Dsouza S., Khamis A.H. et al. Noninvasive Assessment of the Severity of Liver Fibrosis in MASLD Patients with Long-Standing Type 2 Diabetes // J. Gen. Intern. Med. 2025. Vol. 40, No. 10. P. 2309–2318. doi: 10.1007/s11606-025-09348-2.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Higashi M., Tanabe M., Yamane M. et al. Impact of fat on the apparent T1 value of the liver: assessment by water-only derived T1 mapping // Eur Radiol. 2023. Vol. 33, No. 10. P. 6844–6851. doi: 10.1007/s00330-023-10052-0.</mixed-citation><mixed-citation xml:lang="en">Higashi M., Tanabe M., Yamane M. et al. Impact of fat on the apparent T1 value of the liver: assessment by water-only derived T1 mapping // Eur Radiol. 2023. Vol. 33, No. 10. P. 6844–6851. doi: 10.1007/s00330-023-10052-0.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Mesropyan N., Kupczyk P.A., Dold L. et al. Assessment of liver cirrhosis severity with extracellular volume fraction MRI // Sci Rep. 2022. Vol. 8, No. 12. P. 9422. doi: 10.1038/s41598-022-13340-9.</mixed-citation><mixed-citation xml:lang="en">Mesropyan N., Kupczyk P.A., Dold L. et al. Assessment of liver cirrhosis severity with extracellular volume fraction MRI // Sci Rep. 2022. Vol. 8, No. 12. P. 9422. doi: 10.1038/s41598-022-13340-9.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang H., Hao E., Xia D. et al. Estimating liver cirrhosis severity with extracellular volume fraction by spectral CT // Sci Rep. 2025. Vol. 26, No. 15. P. 18343. doi: 10.1038/s41598-025-03717-x.</mixed-citation><mixed-citation xml:lang="en">Zhang H., Hao E., Xia D. et al. Estimating liver cirrhosis severity with extracellular volume fraction by spectral CT // Sci Rep. 2025. Vol. 26, No. 15. P. 18343. doi: 10.1038/s41598-025-03717-x.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Maino C., Vernuccio F., Cannella R. et al. Non-invasive imaging biomarkers in chronic liver disease // Eur. J. Radiol. 2024. Vol. 181. P. 111749. doi: 10.1016/j.ejrad.2024.111749.</mixed-citation><mixed-citation xml:lang="en">Maino C., Vernuccio F., Cannella R. et al. Non-invasive imaging biomarkers in chronic liver disease // Eur. J. Radiol. 2024. Vol. 181. P. 111749. doi: 10.1016/j.ejrad.2024.111749.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Mazzola M., Cannella R., Pilato G. et al. Quantitative liver MRI biomarkers: what the radiologist should know // J. Med. Imaging Interv. Radiol. 2024. Vol. 11. P. 13. doi: 10.1186/s44326-024-00013-3.</mixed-citation><mixed-citation xml:lang="en">Mazzola M., Cannella R., Pilato G. et al. Quantitative liver MRI biomarkers: what the radiologist should know // J. Med. Imaging Interv. Radiol. 2024. Vol. 11. P. 13. doi: 10.1186/s44326-024-00013-3.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Catucci D., Obmann V.C., Berzigotti A. et al. Noninvasive assessment of clinically significant portal hypertension using DT1 of the liver and spleen and ECV of the spleen on routine Gd-EOB-DTPA liver MRI // Eur. J. Radiol. 2021. Vol. 144. P. 109958. doi: 10.1016/j.ejrad.2021.109958.</mixed-citation><mixed-citation xml:lang="en">Catucci D., Obmann V.C., Berzigotti A. et al. Noninvasive assessment of clinically significant portal hypertension using DT1 of the liver and spleen and ECV of the spleen on routine Gd-EOB-DTPA liver MRI // Eur. J. Radiol. 2021. Vol. 144. P. 109958. doi: 10.1016/j.ejrad.2021.109958.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
